Clinical trials: Gastrointestinal Disorder, Functional
Hepatitis B, Chronic
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional…
- Trial name
- NCT04465916
- Testing
- EYP001a, Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
- Where
- 18 sites in Australia, Hong Kong and 2 more
- Volunteers
- 26 people
- Sponsor
- Enyo Pharma
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Irritable Bowel Syndrome
Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo
The study shall prove whether treatment of irritable bowel syndrome with Iberogast is superior to placebo regarding the main criterium "pain"
- Trial name
- NCT01940848
- Testing
- STW5 (Iberogast, BAY98-7411)
- Where
- 19 sites in Germany
- Volunteers
- 243 people
- Sponsor
- Bayer
Irritable Bowel Syndrome-IBS
Evaluate the Safety of Linaclotide in IBS-C Patients in China
This is a Multi-center, single arm, observational study to evaluate the safety of linaclotide in IBS-C patients in China. Enrolls approximately 3,000 Chinese patients from 30 participating sites around China and followed up for…
- Trial name
- Liberty (NCT04462900)
- Where
- 29 sites in China
- Volunteers
- 3,028 people
- Sponsor
- AstraZeneca
IBS - Irritable Bowel Syndrome
Effect of Postbiotic Product on Colonic Barriers in IBS
Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS).
- Trial name
- NCT05475314
- Testing
- ReFerm(R)
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Nordisk Rebalance A/S
Diabetes Mellitus, Type 2, Liver Diseases
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders
This is a prospective, multicentric, non-treatment study to build and validate a portable, non-invasive smart breath analyzer that can screen underlying health issues using exhaled breath.
- Conditions
- Diabetes Mellitus, Type 2, Liver Diseases, Kidney Diseases, Lung Diseases
- Trial name
- RESPYR-SBA (NCT07646015)
- Where
- India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Respyr
Functional Gastrointestinal Disorders
Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula
This study aims to assess the evolution of functional gastrointestinal disorders (FGIDs) in infants fed with a new infant formula, using the Gastrointestinal (GI) and gastroesophageal reflux (GER) (GIGER) scale through an…
- Trial name
- NCT06488274
- Testing
- New infant formula
- Where
- 4 sites in France
- Volunteers
- 139 people
- Sponsor
- United Pharmaceuticals
Irritable Bowel Syndrome With Diarrhea
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-05 (NCT02320318)
- Testing
- Ibodutant 10 mg
- Where
- 20 sites in Singapore, South Korea and 1 more
- Sponsor
- Menarini Group
Hepatocellular Carcinoma (HCC)
Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma
This is a Phase 1, open-label, multicenter, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CT-01, administered either as monotherapy or…
- Trial name
- NCT06994572
- Testing
- CT-01, EVEROLIMUS
- Volunteers
- 141 people
- Sponsor
- Captor Therapeutics S.A.
IBS (Irritable Bowel Syndrome), IBD (Inflammatory Bowel Disease)
Efficacy of PosBion® Postbiotic Supplementation in Adults With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits, often associated with impaired intestinal barrier function, low-grade…
- Conditions
- IBS (Irritable Bowel Syndrome), IBD (Inflammatory Bowel Disease), Gut Health
- Trial name
- NCT07699926
- Testing
- Postbiotic supplementation
- Where
- Malaysia
- Volunteers
- 55 people
- Sponsor
- My Myracle Sdn.Bhd
Irritable Bowel Syndrome
Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: Strategy A = MeteoSpasmyl®, on-demand therapy Strategy B = standard of care chosen by the physician
- Trial name
- NCT01404923
- Testing
- anti spasmodic agents, alverine citrate, simeticone
- Volunteers
- 436 people
- Sponsor
- Laboratoires Mayoly Spindler
Irritable Bowel Syndrome, Vaginal Health
A Single Group Study to Evaluate the Effects of a Vaginal Probiotic on Vaginal and Digestive Health
This is a virtual single-group study that will last 12 weeks. Participants will take 1 capsule every day, with water. Questionnaires will be completed at baseline, 2 weeks, 4 weeks, and 12 weeks.
- Trial name
- NCT06124313
- Testing
- Vaginal Probiotic
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rael
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers
This is a three-period crossover study to compare GW876008 and placebo to see if GW876008 will normalise blood flow responses after different emotional stimuli.
- Trial name
- NCT00376896
- Testing
- GW876008 200mcg, GW876008 20mcg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline